Effect of a Neuromuscular Electrical Stimulation Program on Walking Capacity in Peripheral Artery Disease Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

120 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-01-09

Study Completion Date

2022-11-22

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Lower extremity peripheral arterial disease (LEPAD) is a highly prevalent chronic disease. Cardiovascular mortality of LEPAD patients at five years ranges between 18 to 30%. LEPAD is primarily caused by atherosclerosis that induces an inadequate blood flow to meet the tissues demand due to the narrowing of the arteries. An aggravation of the arterial lesions in LEPAD patients induces a worsening of patients' symptoms and a severe limitation of their walking capacity, contributing to an impairment of their quality of life.

Interventions designed to improve walking impairment may have a significant impact on the functional capacity in LEPAD patients. Lower extremity electrical stimulation is an older technique that relies on different types of electrical stimulations with different expected physiological effects on hemodynamics, skeletal muscle functions or pain pathway. The aim of the ELECTRO-PAD study is to assess the effect of a 12 weeks program of neuromuscular electrical stimulation (NMES) on the absolute walking distance (AWD) measured during a treadmill test in peripheral artery disease patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Arterial Inflow and Muscle Ischemia During Calf Stimulation With the Veinoplus Device

NCT01592812

Peripheral Artery Disease

COMPLETED PHASE4

Transcutaneous Electrostimulation for Intermittent Claudication Supervised Walking Therapy for Intermittent cLAudication

NCT03512912

Intermittent Claudication Peripheral Arterial Disease

UNKNOWN

Effect of Transcutaneous Electrical Nerve Stimulation in Peripheral Artery Disease TENS-PAD Study / TENS-AOMI

NCT02678403

Peripheral Artery Disease

TERMINATED NA

Effect of Lower Leg Heating and Transcutaneous Electrical Nerve Stimulation on Exercise Capacity in Patients With PAD

NCT03462472

Peripheral Arterial Disease

UNKNOWN NA

Effect of Neuromuscular Electrostimulation on Sympathetic Nerve Activity in Patients With Type 2 Diabetes (ELECTROSYMP2)

NCT02171351

Type 2 Diabetes Insulin Resistance

WITHDRAWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The aim of the ELECTRO-PAD study is to assess the effect of a 12 weeks program of neuromuscular electrical stimulation (NMES) on the absolute walking distance (AWD) measured during a treadmill test in peripheral artery disease patients.

Arteriopatic patients will be randomized in 2 groups :

* patients submitted to a 12 weeks program of neuromuscular electrical stimulation (NMES group)
* patients without any program (control group) All patients will also receive a study participation guide that will include an information leaflet outlining tips for active living and walking.

After eligibility criteria will be assessed, patient will be included and randomized (visit 1). A second visit will be performed after 12 weeks (visit 2).

In parallel, 2 ancillary studies will be performed :

* Among Rennes' arteriopatic patients, endothelial function will be assessed using measures from 40 patients. Assessment will be done between 1 and 14 days after visit 1 (visit 1')
* The second ancillary study concerns 40 volunteers with no cardiac or vascular pathology, only in the coordinating center Rennes. The same measures will be performed for these volunteers and for arteriopatic patients.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Arteriopathy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Investigators

Investigators won't know which arm is allocated to arteriopathic patients. Program will be send to patients by a outcome research engineer

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients achieving neuromuscular electrical stimulation

LEPAD patients achieving a 12-week program of neuromuscular electrical stimulation. Group of arteriopathic patients who will perform electrostimulation sessions at home and independently. These patients will also receive a study participation guide that will include an information leaflet outlining tips for active living and walking.

Group Type EXPERIMENTAL

neuromuscular electrical stimulator

Intervention Type DEVICE

A 12-week program of neuromuscular electrical stimulation

Control

Group of artriopathic patients who will maintain their usual drug management. These patients will also receive a study participation guide that will include an information leaflet outlining tips for active living and walking.

Group Type OTHER

Advices

Intervention Type OTHER

The usual practice associated with an information leaflet outlining tips for active living and walking.

Healthy volunteers

Ancillary study. Participants will perform a precise program of walking sessions performed outdoors and independently and the same biological parameters as those assessed in arteriopathic patients will be assessed

Group Type OTHER

Walking sessions

Intervention Type OTHER

A 12-week program of walking sessions performed outdoors and independently

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

neuromuscular electrical stimulator

A 12-week program of neuromuscular electrical stimulation

Intervention Type DEVICE

Walking sessions

A 12-week program of walking sessions performed outdoors and independently

Intervention Type OTHER

Advices

The usual practice associated with an information leaflet outlining tips for active living and walking.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Arteriopatic patients :

* Age \> 40 years old.
* Subjects with Lower Extremity Peripheral Artery disease (LEPAD). LEPAD is defined by the presence of at least one of the following criteria:

* History of revascularization in the lower limbs due to LEPAD; OR
* Ankle brachial index (ABI) of ≤ 0.90; OR
* ABI or ankle systolic blood pressure decrease during recovery from treadmill walking test \> 20 % or \> 30 mmHg, respectively; OR
* Toe-brachial index ≤0.70 if ABI cannot be measured and if incompressible arteries are suspected.
* Complain of exertional calf pain (fatigue, discomfort or cramping) that can begin or not at rest, causes the participant to stop walking and relieves or lessens within 10 minutes of rest (assessed using the San Diego questionnaire AND confirmed during treadmill testing);
* Pain (fatigue, discomfort or cramping) is mainly located at the calves' level.
* Maximal walking distance on treadmill \< 300 m (treadmill protocol 3.2 km/h, 10% grade);
* Subject receiving from at least one month the recommend medical therapy for LEPAD management (antiplatelet therapy and statin medication).
* Obtained informed consent.

Healthy volunteers

* Age \> 50 years old;
* Absence of pain reported in the lower limbs during walking as supported by a negative score in the San Diego Questionnaire;
* Absence of any functional limitation during the treadmill walking test: 15 min of walking at 3.2 km/h and 10% slope;
* ABI ≥1.00 and ≤1.40.
* Obtained informed consent.

Exclusion Criteria

Arteriopatic patients :

* Patients with a pacemaker or defibrillator;
* Patients with acute or critical limb ischemia;
* Ambulation limited by exertional symptoms other than intermittent claudication (e.g., dyspnea or angina pectoris);
* Ambulation limited by exertional symptoms indicative of intermittent claudication but affecting muscles in the lower extremities other than the calves;
* Contraindication to exercise testing according to the American Heart Association and the American College of Sports Medicine;
* Major cardiovascular event (myocardial infarction or stroke) or major surgery within the previous three months before inclusion;
* Female patients who are pregnant, planning to become pregnant, or lactating;
* Known presence of an aneurysm of the abdominal aorta \> 4cm or an aneurysm of the iliac artery \>1.5cm;
* Patient subject to legal protection (guardianship or tutelage measure) and persons deprived from their liberty (according to French law);
* Simultaneous participation to another ongoing clinical research protocol;
* Unwilling or unable to engage in the completion of a 12 week programme;
* Any planned event(s) that could interfere with the completion of the protocol: e.g., extended holidays preventing the completion of the intervention or planned hospitalization for a prolonged period of time.
* Body mass \> 160 kg (may exceed treadmill limit).
* Inability to understand and sign informed consent forms due to cognitive or language barriers
* LEPAD due to other causes than atherosclerosis.

Healthy volunteers :

* Contraindication to walking;
* ABI \<1.00 or \>1.40;
* Inability to obtain a measure of ABI due to uncompressible arteries;
* Limitation(s) and/or symptoms during the treadmill walking test;
* Treadmill walking test uncompleted.
* Presence of hypertension, heart failure, angina pectoris, diabetes, chronic obstructive pulmonary disease, supported by the presence of a medical treatment and the medical history.
* Presence of conditions likely to cause a functional limitation in walking and/or significant modification of physiological responses to the exercise: current or former smoker from less than 6 months, cancer (ongoing), Parkinson's disease, renal failure (ongoing), supported by the presence of a medical treatment and the medical history.
* History of cardiovascular disease (heart failure, stroke, myocardial infarction) reported by the patient.
* Female volunteers who are pregnant, planning to become pregnant, or lactating;
* Volunteers subject to legal protection (guardianship or tutelage measure) and persons deprived from their liberty (according to French law).
* Simultaneous participation to another ongoing clinical research protocol.

1. Patients requiring a pacemaker or defibrillator within the first three months.
2. For the primary endpoint, patients who underwent revascularisation (surgical or endovascular) in the first three months.

revascularisation (surgical or endovascular) in the first three months.
3. 3\. Any health events during the first three months that no longer allow the patient to follow the protocol.
4. Burning during the electrostimulation sessions;
5. Skin allergy due to the placement of the electro-stimulation electrodes

Minimum Eligible Age

41 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes